Annotation Detail

Information

Associated Genes: BRAF
Associated Variants: BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 )
BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 )
Associated Disease: colorectal cancer
Source Database: CIViC Evidence
Description: Mouse xenografts using HT29 cells harboring the BRAF V600E mutation treated with combination therapy (capecitabine, vemurafenib, bevacizumab) showed increased survival and reduced tumor burden compared to single and double agent therapies.
Variant Origin: somatic
Variant Origin: Somatic
Evidence URL: https://civic.genome.wustl.edu/links/evidence_items/98
Gene URL: https://civic.genome.wustl.edu/links/genes/5
Variant URL: https://civic.genome.wustl.edu/links/variants/12
Rating: 2
Evidence Type: Predictive
Disease: Colorectal Cancer
Evidence Direction: Supports
Drug: Capecitabine,Bevacizumab,Vemurafenib
Evidence Level: D
Clinical Significance: Sensitivity/Response
Pubmed: 22180495

Drugs